Atomoxetine Dosing for Adults
For adults with ADHD, initiate atomoxetine at 40 mg daily and increase after a minimum of 3 days to the target dose of 80 mg daily, with a maximum dose of 100 mg daily if needed after 2-4 additional weeks at 80 mg. 1
Standard Dosing Schedule
Initial Dosing
- Start: 40 mg/day (single morning dose or divided into morning and late afternoon/evening doses)
- Wait minimum 3 days before dose adjustment 1
Target Dosing
- Target: 80 mg/day after the initial 3-day period
- This can be administered as:
- Single daily dose in the morning, OR
- Evenly divided doses (morning and late afternoon/evening) 1
Maximum Dosing
- After 2-4 additional weeks at 80 mg, may increase to maximum 100 mg/day if optimal response not achieved 1
- No data support increased effectiveness at doses higher than 100 mg 1
Critical Dosing Adjustments
Hepatic Impairment
- Moderate hepatic insufficiency (Child-Pugh Class B): Reduce initial and target doses to 50% of normal dose
- Severe hepatic insufficiency (Child-Pugh Class C): Reduce initial and target doses to 25% of normal dose 1
CYP2D6 Poor Metabolizers or Strong CYP2D6 Inhibitor Use
When taking strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) or in known CYP2D6 poor metabolizers:
- Start: 40 mg/day
- Only increase to 80 mg/day if:
- Symptoms fail to improve after 4 weeks, AND
- Initial dose is well tolerated 1
This adjustment is critical because CYP2D6 poor metabolizers have 8-10-fold higher atomoxetine exposure compared to extensive metabolizers 2
Administration Details
- May be taken with or without food 1
- Capsules must be swallowed whole (not opened) 1
- Can be discontinued without tapering 1
- Once-daily dosing is effective and may improve adherence 3
Duration and Monitoring
Time to Assess Efficacy
- Allow 4-6 weeks at target dose before judging efficacy 4
- This is a common pitfall—clinicians often judge response too early or at suboptimal doses
Real-World Dosing Problem
Critical caveat: Real-world data show adults receive an average dose of only ~60 mg/day, well below the recommended 80 mg target 4. This suboptimal dosing is associated with:
- Shorter length of therapy (65.6 days for <80 mg vs 159.3 days for ≥80 mg) 5
- Poor patient outcomes 4
- Only 45% of adult monotherapy patients reach the recommended 80 mg dose 5
Reaching Target Dose
- 71.7% of patients who eventually reach 80 mg do so by Day 30 5
- Patients reaching 80 mg have significantly longer treatment duration 5
Safety Considerations
Pre-Treatment Screening
- Screen for personal or family history of bipolar disorder, mania, or hypomania before initiating 1
Safety Limits
- Single doses >120 mg and total daily doses >150 mg have not been systematically evaluated 1
Common Adverse Events
Most common in adults include: dry mouth, nausea, decreased appetite, constipation, insomnia, dizziness, sweating, dysuria, sexual problems, and palpitations 6, 3
Key Clinical Pearls
The most important clinical action is ensuring patients actually reach and maintain the 80 mg target dose for an adequate duration (4-6 weeks) before concluding treatment failure. 4, 5 The evidence strongly suggests that underdosing is the primary reason for poor outcomes in clinical practice, not medication inefficacy.